Genor Biopharma (6998 HK): First Product Approved in China; Late-Stage Pipeline Entails Visibility

Equity Bottom-Up

280 Views, 09 May 2022 00:57

EXECUTIVE SUMMARY

JHBP (Genor) (6998 HK) received approval in China for its first commercial drug, GB242, a biosimilar to Remicade (infliximab). Approved indications have an addressable patient population of 10 million.
The company is also expected to obtain marketing approval for its drug candidate for the treatment of relapsed and refractory peripheral T-cell lymphoma (PTCL) in China this year.
In-Licensed GB491 (lerociclib) has entered in two phase 3 clinical trials for first and second-line treatments of breast cancer. NDA for GB491 is expected to be filed in 2023.

detail (5-minute read)

WHAT’S TRENDING

Insights